Edistride is a medicine used to treat type 2 diabetes, chronic (long-term) heart failure and chronic kidney disease. In type 2 diabetes, Edistride is used in adults and children from 10 years of age whose condition is not controlled well enough. It is used with appropriate diet and exercise in patients who cannot take metformin (another diabetes medicine). It can also be used as ‘add-on’ treatment to other diabetes medicines. In chronic heart failure (inability of the heart to pump enough blood around the body), Edistride is used in adults who have symptoms of the disease. Edistride is also used in adults with chronic kidney disease. Edistride contains the active substance dapagliflozin.
Therapeutic Indication
### Therapeutic indication **Type 2 diabetes mellitus** Edistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise - as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1. **Heart failure** Edistride is indicated in adults for the treatment of symptomatic chronic heart failure. **Chronic kidney disease** Edistride is indicated in adults for the treatment of chronic kidney disease.
Therapeutic Area (MeSH)
ATC Code
A10BK01
ATC Item
dapagliflozin
Pharmacotherapeutic Group
Drugs used in diabetes
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| dapagliflozin propanediol monohydrate | N/A | 达格列净 |
EMA Name
Edistride
Medicine Name
Edistride
Aliases
N/ANo risk management plan link.
